2026 Pharmaceutical Companies Vaccines 
STAT
AUGUST 22, 2023
The Food and Drug Administration approved a Pfizer vaccine that aims to protect newborns against RSV by vaccinating pregnant people, STAT tells us. The vaccine, marketed as Abrysvo, previously won approval for adults over the age of 60. Continue to STAT+ to read the full story…
STAT
JULY 30, 2024
… Four pharmaceutical companies involved in the negotiations over prices for Medicare do not expect a significant impact on their businesses after seeing confidential suggested prices from the government for their drugs that will take effect in 2026 , Reuters writes.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Express Pharma
JANUARY 12, 2024
Initiatives such as Ayushmaan Bharat Digital Mission (“ADBDM”), CoWIN (a digital vaccine delivery platform), health registry, and telemedicine, highlight the government’s strong emphasis on digitisation of health in India. Expectation #4 Clarification on product samples and low brand value items – According to CBDT circular no.
PharmaShots
FEBRUARY 21, 2023
With the growing influence of radiopharmaceutical companies in oncology, the companies hold a firm grasp on the market. With the expanding acceptance among HCPs, patients, and researchers, radiopharmaceutical companies are estimated to touch the $7.5B threshold by 2026.
pharmaphorum
FEBRUARY 16, 2022
The Life Sciences Vision also identified seven therapeutic areas that are priorities for the government: treatments for neurodegenerative disorders, cancer immunotherapies, novel vaccines, cardiometabolic therapies, treatments for respiratory disorders, therapies for multi-system ageing and treatments for mental illness. About the authors.
pharmaphorum
JUNE 29, 2022
COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. Sarah Rickwood has 30 years’ experience as a consultant to the pharmaceutical industry. appeared first on.
pharmaphorum
JANUARY 6, 2022
IQVIA Institute models global cumulative spend on COVID-19 vaccines to be a base case of $251bn to 2026 , with spend on COVID-19 treatments, including the new oral agents and treatments of post-viral syndromes, likely to add significant incremental spend. Medicine budget constraint, structural fund largesse.
Expert insights. Personalized for you.
246 
Let's personalize your content